CGTX

Cognition Therapeutics Inc

0.9798

Jul 21 • 12:18PM ET +0.0312 (3.29%)

Healthcare Biotechnology USA Micro NASD

Peers: AARD AGEN CNTB GALT IMUX KLRS KZIA NTHI SPRO VRCA

Index	-
Market Cap	87.69M
Enterprise Value	56.93M
Income	-19.58M
Sales	0.00M
Book/sh	0.33
Cash/sh	0.35
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	14
IPO	Oct 08, 2021

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	2.93
P/C	2.81
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	5.92
Current Ratio	5.92
Debt/Eq	0.02
LT Debt/Eq	0.01
Option/Short	No / Yes

EPS (ttm)	-0.26
EPS next Y	-0.28
EPS next Q	-0.06
EPS this Y	-0.78%
EPS next Y	14.21%
EPS next 5Y	-10.35%
EPS past 3/5Y	24.09% 10.12%
Sales past 3/5Y	- -
EPS Y/Y TTM	64.57%
Sales Y/Y TTM	-
EPS Q/Q	62.68%
Sales Q/Q	-
Earnings	May 07 AMC
EPS/Sales Surpr.	25.93% -

Insider Own	8.61%
Insider Trans	0.38%
Inst Own	18.76%
Inst Trans	1.06%
ROA	-65.65%
ROE	-92.82%
ROIC	-65.07%
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	-9.56%
SMA50	-17.22%
SMA200	-24.99%
Trades

Shs Outstand	89.35M
Shs Float	81.79M
Short Float	8.64%
Short Ratio	4.59
Short Interest	7.07M
52W High	3.83 -74.42%
52W Low	0.55 78.11%
Volatility	7.25% 13.09%
ATR (14)	0.11
RSI (14)	40.88
Beta	1.78
Rel Volume	0.36
Avg Volume	1.54M
Volume	252,989

Perf Week	-2.99%
Perf Month	-32.43%
Perf Quarter	-12.52%
Perf Half Y	-32.89%
Perf YTD	-27.42%
Perf Year	39.97%
Perf 3Y	-48.16%
Perf 5Y	-
Perf 10Y	-
Recom	1.00
Target Price	3.50
Prev Close	0.95
Price	0.98
Change	3.29%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-19-24	Upgrade	B. Riley Securities	Neutral → Buy	$1 → $1.50
Jul-30-24	Downgrade	Cantor Fitzgerald	Overweight → Neutral
Nov-03-21	Initiated	Oppenheimer	Outperform	$22
Nov-03-21	Initiated	B. Riley Securities	Buy	$27

Jul-13-26 07:30AM	Cognition Therapeutics Participating in Fireside Chat at B. Riley Securities' Mind, Muscle & Vision Summit (GlobeNewswire) -6.42%
Jun-24-26 11:47AM	Cognition Therapeutics Gets Positive FDA Feedback Over Phase 3 Study Of DLB Psychosis But CGTX Stock Just Crashed 33% (Stocktwits) -38.18%
08:46AM	Cognition Therapeutics Advances After FDA Supports Key Elements of Pivotal Trial Plan (CGTX) (InvestorsHub)
07:30AM	Cognition Therapeutics Aligns on Key Aspects of Pivotal Study for Zervimesine (CT1812) in DLB Psychosis Following Receipt of FDA Meeting Minutes (GlobeNewswire)
Jun-16-26 07:30AM	Cognition Therapeutics Announces New Composition of Matter Patent, Extending Patent Protection for Lead Candidate, Zervimesine (CT1812) Through 2045 (GlobeNewswire)
07:30AM	Loading…
Jun-01-26 07:30AM	Cognition Therapeutics Participating in Upcoming Investor Conferences (GlobeNewswire) +5.93%
May-21-26 07:30AM	Cognition Therapeutics Completes Meeting with FDA for Zervimesine (CT1812) in Dementia with Lewy Bodies with Psychosis (GlobeNewswire)
May-14-26 07:30AM	Cognition Therapeutics Receives Second Philanthropic Donation to Extend Ongoing Expanded Access Program for Zervimesine (CT1812) in Dementia with Lewy Bodies (GlobeNewswire)
May-12-26 08:35AM	Hantavirus Outbreak Shows Need for Broad-Spectrum Antiviral Drugs (Exec Edge)
May-07-26 04:15PM	Cognition Therapeutics Reports Financial Results for the First Quarter 2026 and Provides Business Update (GlobeNewswire) -5.69%
08:35AM	NanoViricides to Participate at D. Boral Capital Global Conference in NYC (Exec Edge)
May-06-26 08:35AM	NanoViricides Measles Treatment Granted Orphan Drug Designation by FDA (Exec Edge)
Apr-07-26 07:30AM	Cognition Therapeutics to Present at Needham Virtual Healthcare Conference (GlobeNewswire)
Mar-31-26 04:30PM	Cognition Therapeutics CEO Issues Letter to Shareholders (GlobeNewswire) +27.73% +17.37%
Mar-26-26 03:02PM	Cognition Therapeutics Inc (CGTX) Q4 2025 Earnings Call Highlights: Promising Developments in ... (GuruFocus.com)
07:30AM	Loading…
07:30AM	Cognition Therapeutics Reports Year End 2025 Financial Results and Provides Clinical Development Update (GlobeNewswire)
Mar-23-26 07:30AM	Cognition Therapeutics to Report Fourth Quarter and Year End 2025 Financial Results (GlobeNewswire) +5.61%
Mar-17-26 07:30AM	Cognition Therapeutics Presents Evidence of Zervimesine's Impact on Neuropsychiatric Symptoms of Dementia with Lewy Bodies at AD/PD 2026 (GlobeNewswire) +6.48%
Mar-02-26 07:30AM	Cognition Therapeutics Advancing Zervimesine (CT1812) for Dementia with Lewy Bodies (DLB) Psychosis (GlobeNewswire)
Feb-05-26 07:30AM	Cognition Therapeutics Extends Expanded Access Program for Zervimesine (CT1812) in Dementia with Lewy Bodies (GlobeNewswire)
Jan-27-26 07:30AM	Cognition Therapeutics Completes Type C Meeting with FDA for Zervimesine (CT1812) in Dementia with Lewy Bodies (GlobeNewswire)
Jan-06-26 07:30AM	Cognition Therapeutics Publishes Phase 2 Clinical Results Showing Zervimesine's Potential to Slow the Progression of Dementia with Lewy Bodies (GlobeNewswire)
Dec-03-25 07:30AM	Cognition Therapeutics Reaches Full Enrollment in Expanded Access Program for Zervimesine (CT1812) in Dementia with Lewy Bodies (GlobeNewswire) +11.80%
Dec-01-25 07:30AM	Cognition Therapeutics Presents Phase 3 Plan for Zervimesine (CT1812) in Alzheimer's Disease at Clinical Trials on Alzheimer's Disease (CTAD) Conference (GlobeNewswire) -7.47%
Nov-20-25 04:01PM	Cognition Therapeutics to Participate in 37th Annual Piper Sandler Healthcare Conference (GlobeNewswire)
Nov-13-25 07:36AM	Cognition Therapeutics Completes Enrollment in Phase 2 Study of Zervimesine (CT1812) in Early Alzheimer's Disease (GlobeNewswire) -10.47%
Nov-06-25 07:30AM	Cognition Therapeutics Reports Financial Results for the Third Quarter 2025 and Highlights Progress Across Clinical Programs (GlobeNewswire)
Oct-27-25 09:40AM	Has ANI Pharmaceuticals (ANIP) Outpaced Other Medical Stocks This Year? (Zacks)
Oct-08-25 12:00PM	Cognition Therapeutics (CGTX) Moves to Buy: Rationale Behind the Upgrade (Zacks)
Sep-03-25 07:30AM	These Were the 5 Top-Performing Stocks in the Nasdaq Composite in August 2025 (Motley Fool)
07:30AM	Loading…
07:30AM	Cognition Therapeutics Study of Zervimesine (CT1812) in Early Alzheimer's Disease Reaches 75% Enrollment Target (GlobeNewswire)
Sep-02-25 04:00PM	Cognition Therapeutics Closes $30 Million Registered Direct Offering to Two New Fundamental Institutional Investors, Including a Preeminent Global Investment Firm to Support Phase 3 Development of Zervimesine (CT1812) (GlobeNewswire)
Aug-27-25 08:53PM	Cognition Therapeutics Announces $30 Million Registered Direct Offering of Common Stock (GlobeNewswire) +7.18% -18.95%
Aug-26-25 04:00PM	Cognition Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement (GlobeNewswire) -10.22%
Aug-25-25 10:30AM	BC-Most Active Stocks (Associated Press Finance) +13.17%
Aug-13-25 10:30AM	BC-Most Active Stocks (Associated Press Finance) +10.91%
Aug-12-25 04:00PM	Cognition Therapeutics Receives End-of-Phase 2 Meeting Minutes Confirming Alignment with U.S. FDA on Registrational Path for Zervimesine (CT1812) in Alzheimer's Disease (GlobeNewswire) +28.10%
Aug-07-25 04:00PM	Cognition Therapeutics Reports Financial Results for the Second Quarter 2025 and Highlights Progress Across Clinical Programs (GlobeNewswire) +11.45%
Jul-29-25 07:30AM	Cognition Therapeutics Presents Data at AAIC Highlighting Broad Neurological Impact of Zervimesine (CT1812) in Dementia with Lewy Bodies and Alzheimer's Disease (GlobeNewswire) -6.28%
Jul-21-25 07:30AM	Cognition Therapeutics Publishes Proteomic Analysis Elucidating Zervimesine's Protection of Neurons and Synapses in Alzheimer's Disease (GlobeNewswire) +7.03%
Jul-16-25 07:30AM	Cognition Therapeutics' Positive Clinical Data from Zervimesine (CT1812) Phase 2 Study in Dementia with Lewy Bodies (DLB) will be Presented in a Podium Presentation at AAIC (GlobeNewswire) +8.56%
Jul-11-25 07:22PM	Cognition Therapeutics, Inc. (CGTX) Retains Buy Rating on START Study Progress (Insider Monkey) -18.91% +6.63%
Jul-10-25 07:30AM	Cognition Therapeutics Completes End-of-Phase 2 Meeting with FDA for Zervimesine (CT1812) in Alzheimer's Disease (GlobeNewswire) +31.45%
Jul-01-25 07:30AM	Cognition Therapeutics Study of Zervimesine (CT1812) in Early Alzheimer's Disease Surpasses 50% Enrollment Target (GlobeNewswire)
Jun-25-25 07:30AM	Cognition Therapeutics Provides Regulatory Update on Zervimesine (CT1812) in Alzheimer's Disease and Dementia with Lewy Bodies (DLB) (GlobeNewswire)
Jun-03-25 07:30AM	Philanthropic Donor Funds Cognition Therapeutics' Expanded Access Program for Zervimesine (CT1812) in Dementia with Lewy Bodies (GlobeNewswire)
May-28-25 07:30AM	Cognition Therapeutics Releases New Episode of "Conversations" Podcast: Studying the Patient/Caregiver Lived Experience in Dementia with Lewy Bodies (GlobeNewswire) -5.76%
May-09-25 11:31AM	Cognition announces outcomes from trial of zervimesine for geographic atrophy (Clinical Trials Arena) -8.76%
07:30AM	Cognition Therapeutics Presented Data at Association for Research in Vision and Ophthalmology Showing Impact on Retinal Cell Health (GlobeNewswire)
May-08-25 07:30AM	Cognition Therapeutics Reports Topline Results Showing Oral Zervimesine (CT1812) Reduced Lesion Growth in Phase 2 Study in Geographic Atrophy (GlobeNewswire) -6.96%
May-07-25 07:30AM	Cognition Therapeutics Reports Financial Results for the First Quarter 2025 and Provides Business Update (GlobeNewswire) -15.04%
Apr-01-25 07:30AM	Cognition Therapeutics Presents Results at AD/PD 2025 Showing Impact of Zervimesine (CT1812) on Alzheimer's Disease Processes (GlobeNewswire) -6.82%
Mar-25-25 07:30AM	Cognition Therapeutics to Report Biomarker Results from Phase 2 SHINE Study in Mild-to-Moderate Alzheimer's Disease in Podium Presentation at AD/PD 2025 (GlobeNewswire) -6.23%
Mar-21-25 03:01AM	Cognition Therapeutics Inc (CGTX) Q4 2024 Earnings Call Highlights: Strategic Focus on ... (GuruFocus.com) +6.61%
12:18AM	Q4 2024 Cognition Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
Mar-20-25 01:15PM	Cognition Therapeutics, Inc (CGTX) Q4 2024 Earnings Call Transcript (SeekingAlpha) -5.18%
07:00AM	Cognition Therapeutics Reports Year End 2024 Financial Results and Provides Business Update (GlobeNewswire)
Mar-14-25 08:35AM	Life Science Virtual Investor Forum: Presentations Now Available for Online Viewing (GlobeNewswire) +7.81%
Mar-13-25 04:05PM	Cognition Therapeutics to Report Fourth Quarter and Full Year 2024 Results (GlobeNewswire)
Mar-12-25 04:05PM	Cognition Therapeutics Granted Extension to Meet Nasdaq Minimum Bid Price Requirement for Continued Exchange Listing (GlobeNewswire)
01:12PM	Life Sciences Investor Forum Agenda Announced for March 13th (GlobeNewswire)
Mar-10-25 07:30AM	Cognition Therapeutics to Present at Life Sciences Virtual Investor Conference (GlobeNewswire)
Feb-27-25 07:30AM	Cognition Therapeutics Publishes Research Supporting the Potential of Zervimesine in Dry AMD (GlobeNewswire) -7.41%
Feb-26-25 07:00AM	Cognition Therapeutics Successfully Passes Pre-defined Futility Analysis of Phase 2 Study of Oral Zervimesine (CT1812) in Geographic Atrophy (GlobeNewswire)
Feb-25-25 07:30AM	Cognition Therapeutics' VP of Research Co-hosting Precision Medicine Workshop at the Neuroimmunology Drug Development Summit (GlobeNewswire) -7.87%
Feb-20-25 07:30AM	Cognition Therapeutics Announces Publication of Commercial Manufacturing Process for Lead Alzheimer's Candidate, Zervimesine (CT1812) (GlobeNewswire)
Jan-30-25 07:30AM	Cognition's Positive Phase 2 'SHIMMER' Study of Zervimesine (CT1812) in Dementia with Lewy Bodies (DLB) will be Presented in a Podium Presentation at ILBDC (GlobeNewswire)
Jan-08-25 04:14PM	Cognition Therapeutics CEO Participating in Longwood and Sachs Conferences (GlobeNewswire)
Dec-20-24 07:21AM	B. Riley upgrades Cognition Therapeutics to Buy on Lewy bodies data (TipRanks)
Dec-19-24 07:31AM	Cognition Therapeutics announces results in Phase 2 study of CT1812 (TipRanks) +9.31%
Dec-18-24 07:22AM	Cognition Therapeutics Announces Positive Results in Phase 2 Study of CT1812 in Dementia with Lewy Bodies (GlobeNewswire) +27.50%
Nov-28-24 09:55AM	Cognition Therapeutics (CGTX) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now (Zacks)
Nov-26-24 07:40AM	Cognition Therapeutics provided an update on Phase 2 SHINE study analysis (TipRanks)
07:30AM	Cognition Therapeutics Announces all Participants have Completed their Final Visits in the Phase 2 SHIMMER Study of CT1812 in Dementia with Lewy Bodies (GlobeNewswire)
Nov-25-24 07:30AM	Cognition Therapeutics' Analysis Correlates Biomarker Changes with Cognitive Benefit in Alzheimer's Population (GlobeNewswire)
Nov-15-24 08:35AM	Life Sciences Investor Forum: Presentations Now Available for Online Viewing (GlobeNewswire) -9.85%
Nov-13-24 07:30AM	Cognition Therapeutics Reports Financial Results for the Third Quarter 2024 and Provides Business and Clinical Update (GlobeNewswire) -10.24%
Nov-12-24 08:35AM	Life Sciences Investor Forum Agenda Announced for November 14th (GlobeNewswire) +18.00%
07:30AM	Cognition Therapeutics to Present at Zacks SCR Life Sciences Investor Forum (GlobeNewswire)
Oct-31-24 04:15PM	Cognition Therapeutics Presents Poster of Participant Demographics from Phase 2 Dementia with Lewy Bodies Study at CTAD (GlobeNewswire) -11.09%
Oct-29-24 12:55PM	Cognition Therapeutics Announces Results of Pre-specified Analysis of SHINE Study Data Presented at CTAD (GlobeNewswire) +5.15%
Oct-23-24 07:30AM	Analyses from Cognition's Positive Phase 2 'SHINE' Study of CT1812 in Mild-to-Moderate Alzheimer's Disease will be Presented in a Podium Presentation at CTAD (GlobeNewswire) +24.35%
Oct-22-24 07:30AM	Cognition Therapeutics Releases New Episode of Conversations Podcast: Executing Clinical Research in Dementia with Lewy Bodies (DLB) (GlobeNewswire)
Oct-09-24 05:37PM	Cognition Therapeutics Inc (CGTX) Q2 2024 Earnings Call Highlights: Promising Alzheimer's Trial ... (GuruFocus.com)
Oct-02-24 07:30AM	Cognition Therapeutics Will Participate in the Roth Healthcare Opportunities Conference (GlobeNewswire)
Oct-01-24 07:30AM	Cognition Therapeutics Supports Lewy Body Dementia Awareness Month and the Need for Improved Treatments for the Second Most Common Dementia (GlobeNewswire) -6.06%
Sep-03-24 07:30AM	Cognition Therapeutics to Participate in Upcoming September 2024 Investor Conferences (GlobeNewswire) -10.88%
Aug-22-24 07:31AM	Cognition Therapeutics Publishes EEG Findings from Phase 2 SEQUEL Study of CT1812 in Mild-to-Moderate Alzheimer's Disease (GlobeNewswire)
Aug-08-24 07:00AM	Cognition Therapeutics Reports Financial Results for the Second Quarter 2024 and Provides Business and Clinical Update (GlobeNewswire)
Aug-05-24 07:30AM	Cognition Therapeutics to Report Second Quarter 2024 Financial Results (GlobeNewswire) -9.95%
Jul-30-24 06:32AM	Cognition Therapeutics stock dips 43% following trial results for Alzheimers candidate (Clinical Trials Arena) -17.29%
Jul-29-24 11:58AM	Tivic Health Systems (TIVC) Stock Pops Another 39% (InvestorPlace) -43.88%
07:00AM	Cognition Therapeutics' Proof-of-Concept Phase 2 SHINE Trial Demonstrates Consistent Improvement in Cognitive Outcomes with Once-Daily Oral CT1812 in Mild-to-Moderate Alzheimer's Patients (GlobeNewswire)
Jul-26-24 04:11PM	Cognition Therapeutics to Host Investor Webcast to Discuss Results from Proof-of-Concept Phase 2 SHINE Study of CT1812 in Mild-to-Moderate Alzheimer's Disease at 8:30am ET on Monday July 29, 2024 (GlobeNewswire) +12.86%
Jul-02-24 07:30AM	Results from Cognition Therapeutics' Phase 2 SHINE Study of CT1812 in Mild-to-Moderate Alzheimer's Disease Accepted for Presentation at AAIC (GlobeNewswire) +8.98%
May-21-24 07:30AM	Cognition Therapeutics Releases New Episode of Conversations Podcast: Protecting the Synapse from Amyloid Toxicity in Alzheimer's Disease (GlobeNewswire) +8.10%
May-07-24 01:53PM	CGTX Stock Earnings: Cognition Therapeutics Beats EPS for Q1 2024 (InvestorPlace)
07:30AM	Cognition Therapeutics Reports Financial Results for the First Quarter 2024 and Provides Business Update (GlobeNewswire)
Apr-29-24 07:30AM	Cognition Therapeutics Completes Enrollment in Phase 2 SHIMMER Study of CT1812 in Mild-to-Moderate Dementia with Lewy Bodies (GlobeNewswire)
Apr-22-24 07:30AM	Cognition Therapeutics KOL Event Provided Platform for Valuable Discussion of Current Therapeutic Options and Need for Additional Options to Treat Alzheimer's Disease (GlobeNewswire)

Cognition Therapeutics, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery and development of innovative, small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system, or CNS, and retina. It offers the CT1812 which aims to restore the damaged cellular processes that drive diseases such as Alzheimer's disease, dry age-related macular degeneration, geographic atrophy and other conditions. The company was founded by Franz F. Hefti, Gilbert M. Rishton, and Susan M. Catalano on August 21, 2007 and is headquartered in Purchase, NY.

CEOMs. Lisa Ricciardi

Chief Financial OfficerMr. John Brendan Doyle

Ph.D.Dr. Anthony O. Caggiano M.D.

VP & Head of CMCDr. Steven A. Weissman Ph.D.

Head of QualityMs. Anita Cornet

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Doyle John Brendan	Chief Financial Officer	Apr 16 '26	Buy	1.13	10,000	11,300	627,509	Apr 20 04:18 PM
Ricciardi Lisa	CEO & President	Apr 16 '26	Buy	1.10	9,175	10,092	1,715,851	Apr 20 04:16 PM
Caggiano Anthony	Chief Medical Officer	Apr 16 '26	Buy	1.11	10,000	11,100	874,906	Apr 20 04:15 PM
Fletcher Aaron G.L.	Director	Sep 19 '25	Option Exercise	0.84	7,729	6,492	56,229	Sep 23 09:54 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

CGTX

Cognition Therapeutics Inc

Upgrade your Finviz experience